(2-carboxamido)(3-amino)thiophene compounds

ABSTRACT

Compounds represented by Formula (I): 
                 
 
or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1 is 
                 
 
R2 is 
                 
 
and R3 is C 0-4 alkyl, are useful in the treatment of cancer.

This application claims the benefit of Provisional application Ser. Nos.60/438,152, filed Jan. 6, 2003, 60/524,972, filed Nov. 25, 2003, and60/526,358, filed Dec. 2, 2003.

BACKGROUND OF THE INVENTION

The present invention is directed to 2,3-substituted thiophenes. Inparticular, the present invention is directed to(2-carboxamido)(3-amino)thiophenes that are inhibitors of c-Kitproto-oncogene (also known as Kit, CD-117, stem cell factor receptor,mast cell growth factor receptor).

The c-Kit proto-oncogene is believed to be important in embryogenesis,melanogenesis, hematopoiesis, and the pathogenesis of mastocytosis,gastrointestinal tumors, and other solid tumors, as well as certainleukemias, including AML. Accordingly, it would be desirable to developnovel compounds that are inhibitors of the c-Kit receptor.

Many of the current treatment regimes for hyperproliferative disorders(cancer) utilize compounds that inhibit DNA synthesis. Such compounds'mechanism of operation is to be toxic to cells, particularly to rapidlydividing tumor cells. Thus, their broad toxicity can be a problem to thesubject patient. However, other approaches to anti-cancer agents thatact other than by the inhibition of DNA synthesis have been explored totry to enhance the selectivity of the anti-cancer action and therebyreduce adverse side-effects.

It is known that a cell may become cancerous by virtue of thetransformation of a portion of its DNA into an oncogene (i.e. a genewhich, on activation, leads to the formation of malignant tumor cells).Many oncogenes encode proteins that are aberrant protein-tyrosinekinases capable of causing cell transformation. By a different route,the overexpression of a normal proto-oncogenic tyrosine kinase can alsoresult in proliferative disorders, sometimes resulting in a malignantphenotype. Alternatively, co-expression of a receptor tyrosine kinaseand its cognate ligand within the same cell type may also lead tomalignant transformation.

Receptor tyrosine kinases are large enzymes which span the cell membraneand possess i) an extracellular binding domain for growth factors suchas KIT ligand (also known as stem cell factor (SCF), Steel factor (SLF)or mast cell growth factor (MGF)), ii) a transmembrane domain, and iii)an intracellular portion which functions as a kinase to phosphorylatespecific tyrosine residues in proteins. Binding of KIT ligand to KITtyrosine kinase results in receptor homodimerization, the activation ofKIT tyrosine kinase activity, and the subsequent phosphorylation of avariety of protein substrates, many of which are effectors ofintracellular signal transduction, These events can lead to enhancedcell proliferation or promote enhanced cell survival. With some receptorkinases, receptor heterodimerization can also occur.

It is known that such kinases are frequently aberrantly expressed incommon human cancers such as breast cancer, head and neck cancers,gastrointestinal cancer such as colon, rectal or stomach cancer,leukemia, and ovarian, bronchial, lung or pancreatic cancer. Kit kinaseexpression has been documented in a wide variety of human malignanciessuch as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors(GIST), small cell lung carcinoma (SCLC), sinonasal naturalkiller/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma,malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acutemyelogenous leukemia (AML), breast carcinoma, pediatric T-cell acutelymphoblastic leukemia, angiosarcoma, anaplastic large cell lymphoma,endometrial carcinoma, and prostate carcinoma. The kinase activity ofKIT has been implicated in the pathophysiology of several of these—andadditional tumors—including breast carcinoma, SCLC, GIST, germ celltumors, mast cell leukemia, neuroblastoma, AML, melanoma and ovariancarcinoma.

Several mechanisms of KIT activation in tumor cells have been reported,including activating mutations, autocrine and paracrine activation ofthe receptor kinase by its ligand, loss of protein-tyrosine phosphataseactivity, and cross activation by other kinases. The transformingmechanisms initiated by the activating mutations are thought to includedimer formation and increased intrinsic activity of the kinase domain,both of which result in constitutive ligand-independent kinaseactivation, and possibly altered substrate specificity. More than thirtyactivating mutations of the Kit protein have been associated with highlymalignant tumors in humans.

Accordingly, it has been recognized that inhibitors of receptor tyrosinekinases are useful as selective inhibitors of the growth of mammaliancancer cells. For example, Gleevec™ (also known as imatinib mesylate, orSTI571), a 2-phenylpyrimidine tyrosine kinase inhibitor that inhibitsthe kinase activity of the BCR-ABL fusion gene product, was recentlyapproved by the U.S. Food and Drug Administration for the treatment ofCML. Gleevec™, in addition to inhibiting BCR-ABL kinase, also inhibitsthe KIT kinase and PDGF receptor kinase, although it is not effectiveagainst all mutant isoforms of the KIT kinase. Kit ligand-stimulatedgrowth of MO7e human leukemia cells is inhibited by Gleevec™, which alsoinduces apoptosis under these conditions. By contrast, GM-CSF stimulatedgrowth of MO7e human leukemia cells is not affected by Gleevec™.Further, in recent clinical studies using Gleevec™ to treat patientswith GIST, a disease in which KIT kinase is involved in transformationof the cells, many of the patients showed marked improvement.

These studies demonstrate how KIT kinase inhibitors can treat tumorswhose growth is dependent on KIT kinase activity. Other kinaseinhibitors show even greater kinase selectivity. For example, the4-anilinoquinazoline compound Tarceva™ inhibits only EGF receptor kinasewith high potency, although it can inhibit the signal transduction ofother receptor kinases, probably by virtue of the fact that thesereceptors heterodimerize with EGF receptor.

Although anti-cancer compounds such as those described above make asignificant contribution to the art, there is a continuing need forimproved anti-cancer pharmaceuticals, and it would be desirable todevelop new compounds with better selectivity or potency, or withreduced toxicity or side effects.

International Patent Publication No. WO00/27820 describesN-aryl(thio)anthranilic acid amide derivatives. International PatentPublication No. WO99/32477 and U.S. Pat. No. 6,140,351 describeortho-anthranilimide derivatives. International Patent Publication No.WO00/27819 describes anthranilic acid amides. International PatentPublication Nos. WO02/00651 and WO01/19798 describe factor Xainhibitors. International Patent Publication No. WO01/07050 describesnociceptin receptor ORL-1 agonists. U.S. Pat. No. 5,968,965 describesfarnesyl-protein inhibitors. International Patent Publication No.WO01/64642 and U.S. Pat. No. 6,376,515 describe benzamides.International Patent Publication No. WO01/05763 and U.S. Pat. No.6,410,561 describe muscarinic receptor active compounds. U.S. Pat. No.6,410,561 describes amide derivatives.

International Patent Publication No. WO02/066470 describes substitutedalkylamine derivatives. International Patent Publication No. WO02/068406describes substituted amine derivatives International Patent PublicationNo. WO02/055501 describes substituted arylamine derivatives.

U.S. Pat. Nos. 6,207,693 and 6,316,482, and European Patent No.EP0832061 describe benzamide derivatives having vasopressin antagonisticactivity.

SUMMARY OF THE INVENTION

Compounds represented by Formula (I):

or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1 is

R2 is

and R3 is C₀₋₄alkyl, are useful in the treatment of tumors.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a compound represented by Formula(I):

or a pharmaceutically acceptable salt or N-oxide thereof, wherein

R1 is

R2 is

and

R3 is C₀₋₄alkyl.

In one aspect, the present invention is directed to a compoundrepresented by Formula (I), or a pharmaceutically acceptable salt orN-oxide thereof, wherein R2 is

and the other variables are as described above for Formula (I).

In one embodiment of this one aspect, the present invention is directedto a compound represented by Formula (I), or a pharmaceuticallyacceptable salt or N-oxide thereof, wherein R2 is

R3 is hydrogen; and the other variables are as described above forFormula (I).

In a second aspect, the present invention is directed to a compoundrepresented by Formula (I), or a pharmaceutically acceptable salt orN-oxide thereof, wherein R2 is

R3 is C₀₋₄alkyl; and the other variables are as described above forFormula (I).

In an embodiment of this second aspect, the present invention isdirected to a compound represented by Formula (I), or a pharmaceuticallyacceptable salt or N-oxide thereof wherein R2 is

R3 is hydrogen; and the other variables are as described above forFormula (I).

In a third aspect, the present invention is directed to a compoundrepresented by Formula (I), or a pharmaceutically acceptable salt orN-oxide thereof, wherein R2 is

R3 is C₀₋₄alkyl; and the other variables are as described above forFormula (I).

In an embodiment of this third aspect, the present invention is directedto a compound represented by Formula (I), or a pharmaceuticallyacceptable salt or N-oxide thereof, wherein R2 is

R3 is hydrogen; and the other variables are as described above forFormula (I).

In a fourth aspect, the present invention is directed to a compoundrepresented by Formula (I), or a pharmaceutically acceptable salt orN-oxide thereof, wherein R2 is

R3 is C₀₋₄alkyl; and the other variables are as described above forFormula (I).

The present invention is also directed to a method of treatinghyperproliferative disorders, including breast cancer, head cancer, orneck cancer, gastrointestinal cancer, leukemia, ovarian, bronchial,lung, or pancreatic cancer, sinonasal natural killer/T-cell lymphoma,testicular cancer (seminoma), thyroid carcinoma, malignant melanoma,adenoid cystic carcinoma, angiosarcoma, anaplastic large cell lymphoma,endometrial carcinoma, or prostate carcinoma, by administering aneffective amount of a compound represented by Formula II, or apharmaceutically acceptable salt thereof:

wherein:

R11 is aryl, C₃₋₆cycloalkyl or heterocyclyl, each of which optionally issubstituted with 1-6 independent halogen; hydroxy; nitro; amino; acyl;substituted acyl; acylC₁₋₆alkylsulfinyl; acylC₁₋₆alkylsulfonyl; acyloxy;C₁₋₆alkylaminoC₁₋₆alkyl carbamoyloxy; aryl; cyano; heterocyclyl;C₂₋₆alkenyl optionally substituted with acyl, substituted acyl, aryl oracyl-substituted aryl; C₂₋₆alkynyl optionally substituted with amino,acylamino or substituted acylamino; C₁₋₆alkyl optionally substitutedwith halogen, amino, C₁₋₆alkylamino, acylamino, substituted acylamino,hydroxy, acyloxy, acylC₁₋₆alkanoyloxy, acyl, substituted acyl,acylC₁₋₆alkoxyimino, aryl or acyl substituted aryl; C₁₋₆alkylthiooptionally substituted with acyl or substituted acyl; alkoxy optionallysubstituted with aryl, substituted aryl, hydroxy, acyloxy, amino, loweralkylamino, protected amino, heterocyclyl, acyl substituted pyridyl,substituted acyl substituted pyridyl, halogen, acylC₁₋₆alkylamino,N-protected acylC₁₋₆alkylamino, N-acylC₁₋₆alkyl-N-lower alkylamino,acyl, substituted acyl, acylamino, substituted acylamino,C₁₋₆alkylhydrazinocarbonylamino, hydroxyimino, acylC₁₋₆alkoxyimino,substituted acylC₁₋₆alkoxyimino, acylC₁₋₆alkoxy, guanidino orN-protected guanidino; or C₂₋₆alkenyloxy optionally substituted withacyl or substituted acyl substituents;

R21 is hydrogen; lower alkyl optionally substituted with hydroxy, arylor acyl; or cyclo(lower)alkyl;

R31 is hydrogen; halogen; hydroxy; acyloxy; substituted acyloxy;C₁₋₆alkyl optionally substituted with hydroxy or C₁₋₆alkoxy; C₁₋₆alkoxyoptionally substituted with aryl, amino, protected amino, acyl, hydroxy,cyano or C₁₋₆alkylthio; nitro; amino; acyl; substituted acyl; orC₃₋₆cycloalkyloxy;

R₄₁ is hydroxy; halogen; nitro; amino; protected amino; C₁₋₆alkylamino;acyloxy; aminoC₁₋₆alkylamino; N-protected aminoC₁₋₆alkylamino;C₁₋₆alkoxy optionally substituted with hydroxy, aryl, substituted aryl,acyl, substituted acyl, amino, C₁₋₆alkylamino, acylamino, substitutedacylamino, protected amino, heterocyclyl or guanidino; C₁₋₆alkylthiooptionally substituted with acyl, substituted acyl, amino,C₁₋₆alkylamino, acylamino, substituted acylamino, protected amino,heterocyclyl, hydroxy, C₁₋₆alkylsulfonyloxy, arylsulfonyloxy,arC₁₋₆alkoxy or substituted arC₁₋₆alkoxy; C₁₋₆alkyl substituted withacyl, substituted acyl, amino, lower alkylamino, acylamino, substitutedacylamino, protected amino, heterocyclyl, hydroxy, C₁₋₆alkylsulfonyloxyor arylsulfonyloxy; C₂₋₆alkenyl optionally substituted with acyl;C₂₋₆alkynyl optionally substituted with hydroxy, amino, protected amino,C₁₋₆alkylsulfonyloxy or arylsulfonyloxy; aminoC₁₋₆alkylsulfonyl;N-protected aminoC₁₋₆alkylsulfonyl; C₁₋₆alkylaminosulfonyl;heterocyclylsulfonyl; aminoC₁₋₆alkylsulfinyl; N-protectedaminoC₁₋₆alkylsulfinyl; piperidyloxy; or N-protected piperidyloxy;

R₅₁ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy or halogen;

A is a single bond, O or NH;

E is C₁₋₆alkylene, C₂₋₆alkenylene,

or E is a group of the formula —G—J— in which

G is C₁₋₆alkylene and

J is O or

wherein R₆₁ is hydrogen or N-protective group;

X is —CH═CH—, —C═N— or S; and

Y is CH or N.

Compounds of Formula (II) are described in U.S. Pat. No. 6,054,457.

In one aspect, the present invention is directed to a method of treatinghyperproliferative disorders, including breast cancer, head cancer, orneck cancer, gastrointestinal cancer, leukemia, ovarian, bronchial,lung, or pancreatic cancer, sinonasal natural killer/T-cell lymphoma,testicular cancer (seminoma), thyroid carcinoma, malignant melanoma,adenoid cystic carcinoma, angiosarcoma, anaplastic large cell lymphoma,endometrial carcinoma, or prostate carcinoma, by administering aneffective amount of a compound represented by Formula II, or apharmaceutically acceptable salt thereof, wherein X is S, and the othervariables are as described above for Formula II.

In an embodiment of this aspect, the present invention is directed to amethod of treating hyperproliferative disorders, including breastcancer, head cancer, or neck cancer, gastrointestinal cancer, leukemia,ovarian, bronchial, lung, or pancreatic cancer, sinonasal naturalkiller/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma,malignant melanoma, adenoid cystic carcinoma, angiosarcoma, anaplasticlarge cell lymphoma, endometrial carcinoma, or prostate carcinoma, byadministering an effective amount of a compound represented by FormulaII, or a pharmaceutically acceptable salt thereof, wherein X is S: R11is optionally substituted aryl; and the other variables are as describedabove for Formula II.

In another embodiment of this aspect, the present invention is directedto a method of treating hyperproliferative disorders, including breastcancer, head cancer, or neck cancer, gastrointestinal cancer, leukemia,ovarian, bronchial, lung, or pancreatic cancer, sinonasal naturalkiller/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma,malignant melanoma, adenoid cystic carcinoma, angiosarcoma, anaplasticlarge cell lymphoma, endometrial carcinoma, or prostate carcinoma, byadministering an effective amount of a compound represented by FormulaII, or a pharmaceutically acceptable salt thereof, wherein X is S; R11is optionally substituted heterocyclyl; and the other variables are asdescribed above for Formula II.

In still another embodiment of this aspect, the present invention isdirected to a method of treating hyperproliferative disorders, includingbreast cancer, head cancer, or neck cancer, gastrointestinal cancer,leukemia, ovarian, bronchial, lung, or pancreatic cancer, sinonasalnatural killer/T-cell lymphoma, testicular cancer (seminoma), thyroidcarcinoma, malignant melanoma, adenoid cystic carcinoma, angiosarcoma,anaplastic large cell lymphoma, endometrial carcinoma, or prostatecarcinoma, by administering an effective amount of a compoundrepresented by Formula II, or a pharmaceutically acceptable saltthereof, wherein X is S, Y is N, and the other variables are asdescribed above for Formula II.

The present invention is also directed to a method of treatinghyperproliferative disorders, including breast cancer, head cancer, orneck cancer, gastrointestinal cancer, leukemia, ovarian, bronchial,lung, or pancreatic cancer, sinonasal natural killer/T-cell lymphoma,testicular cancer (seminoma), thyroid carcinoma, malignant melanoma,adenoid cystic carcinoma, angiosarcoma, anaplastic large cell lymphoma,endometrial carcinoma, or prostate carcinoma, by administering aneffective amount of a compound represented by Formula III:

wherein:

R12 is aryl, C₃₋₆cycloalkyl or heterocyclyl, each of which optionally issubstituted with 1-6 independent halogen; hydroxy; nitro; protectedamino, amino; acyl; substituted acyl; acylC₁₋₆alkylsulfinyl;acylC₁₋₆alkylsulfonyl; acyloxy; C₁₋₆alkylaminoC₁₋₆alkyl carbamoyloxy;aryl; cyano; heterocyclyl; C₂₋₆alkenyl optionally substituted with acyl,substituted acyl, aryl or acyl-substituted aryl; C₂₋₆alkynyl optionallysubstituted with amino, acylamino or substituted acylamino; C₁₋₆alkyloptionally substituted with halogen, amino, C₁₋₆alkylamino, acylamino,substituted acylamino, hydroxy, acyloxy, acylC₁₋₆alkanoyloxy, acyl,substituted acyl, acylC₁₋₆alkoxyimino, aryl or acyl substituted aryl;C₁₋₆alkylthio optionally substituted with acyl or substituted acyl;alkoxy optionally substituted with aryl, substituted aryl, hydroxy,acyloxy, amino, lower alkylamino, protected amino, heterocyclyl, acylsubstituted pyridyl, substituted acyl substituted pyridyl, halogen,acylC₁₋₆alkylamino, N-protected acylC₁₋₆alkylamino,N-acylC₁₋₆alkyl-N-lower alkylamino, acyl, substituted acyl, acylamino,substituted acylamino, C₁₋₆alkylhydrazinocarbonylamino, hydroxyimino,acylC₁₋₆alkoxyimino, substituted acylC₁₋₆alkoxyimino, acylC₁₋₆alkoxy,guanidino or N-protected guanidino; or C₂₋₆alkenyloxy optionallysubstituted with acyl or substituted acyl substituents;

R22 is hydrogen; C₁₋₆alkyl optionally substituted with hydroxy, aryl oracyl; or C₃₋₆cycloalkyl;

R32 is hydrogen; halogen; hydroxy; acyloxy; substituted acyloxy;C₁₋₆alkyl optionally substituted with hydroxy or C₁₋₆alkoxy; C₁₋₆alkoxyoptionally substituted with aryl, amino, protected amino, acyl, hydroxy,cyano or C₁₋₆alkylthio; nitro; amino; acyl; substituted acyl; orC₃₋₆cycloalkyloxy;

A₁ is a single bond, O, or NH;

E₁ is C₁₋₆alkylene, C₂₋₆alkenylene,

or E₁ is a group of the formula —G1-J1- in which

G1 is C₁₋₆alkylene or

and

J1 is O or

wherein R₆₂ is hydrogen or N-protective group;

X₁ is —CH═CH—, —C═N— or S; and

Y₁ is aryl optionally substituted with 1-6 independent acyl, protectedaminoC₁₋₆alkanoyl, protected amino and nitro, amino and nitro or diaminosubstituents; or Y1 is a condensed heterocyclyl optionally substitutedwith 1-6 halogen, acyl, C₁₋₆alkoxy, hydroxy, guanidino, mercapto,acylamino, amino, heterocyclyl, cyanoamino,aminoC₁₋₆alkyl(C₁₋₆alkyl)amino, C₁₋₆alkylamino,C₁₋₆alkylamino(C₁₋₆alkylamino), substituted heterocyclyl,C₁₋₆alkylhydrazino, aryloxy, C₁₋₆alkylthio, aryl, protected amino,N-protected C₁₋₆alkylamino(C₁₋₆alkyl)amino, N-protectedaminoC₁₋₆alkyl(N′—C₁₋₆alkyl)amino, aminoC₁₋₆alkyl(N—C₁₋₆alkyl)amino,C₁₋₆alkylamino(C₁₋₆alkyl)(N—C₁₋₆alkyl)amino, orC₁₋₆alkoxy(C₁₋₆alkyl)amino substituents, or a C₁₋₆alkyl substituentfurther optionally substituted with aryl, arC₁₋₆alkoxy, cyano,hydroxyimino, mercapto, C₁₋₆alkylamino, acyloxy, halogen, C₁₋₆alkoxy,protected hydroxy, hydroxy, C₁₋₆alkoxyaryl, protected amino, amino,heterocyclyl, or substituted heterocyclyl sub-substituents;

provided that when Y₁ is phenyl optionally substituted with C₁₋₆alkyl oracyl, then

A₁ is a single bond, and

E₁ is

Compounds of Formula (III) are described in U.S. Pat. No. 6,316,482.

In one aspect, the present invention is directed to a method of treatinghyperproliferative disorders, including breast cancer, head cancer, orneck cancer, gastrointestinal cancer, leukemia, ovarian, bronchial,lung, or pancreatic cancer, sinonasal natural killer/T-cell lymphoma,testicular cancer (seminoma), thyroid carcinoma, malignant melanoma,adenoid cystic carcinoma, angiosarcoma, anaplastic large cell lymphoma,endometrial carcinoma, or prostate carcinoma, by administering aneffective amount of a compound represented by Formula III, or apharmaceutically acceptable salt thereof, wherein X₁ is S, and the othervariables are as described above for Formula III.

As used herein, “C₀₋₄alkyl” is used to mean an alkyl having 0-4carbons—that is, 0, 1, 2, 3, or 4 carbons in a straight or branchedconfiguration. An alkyl having no carbon is hydrogen when the alkyl is aterminal group. An alkyl having no carbon is a direct bond when thealkyl is a bridging (connecting) group.

As used herein unless otherwise specified, “alkyl”, “alkenyl”, and“alkynyl” includes straight or branched configurations. Lower alkyls,alkenyls, and alkynyls have 1-6 carbons. Higher alkyls, alkenyls, andalkynyls have more than 6 carbons.

As used herein unless otherwise specified, the terms “aryl” and “ar” arewell known to chemists and include, for example, phenyl and naphthyl, aswell as phenyl with one or more short alkyl groups (tolyl, xylyl,mesityl, cumenyl, di(t-butyl)phenyl). Phenyl, naphthyl, tolyl, and xylylare preferred. “Substituted aryl” is an aryl substituted with suitablesubstituents such as, for example, acyl, substituted acyl, N-protectedpiperazinylsulfonyl, piperazinylsulfonyl,N—C₁₋₆alkylpiperazinylsulfonyl, hydroxyC₁₋₆alkyl, heterocyclyl, halogen,nitro, amino, C₁₋₆alkylamino, cyano, or C₁₋₆alkoxy.

As used herein unless otherwise specified, “heterocyclyl” is well knownto chemists and contains at least one N, S or O hetero-ring atom, andincludes saturated, unsaturated, partially saturated, mono or polycyclicheterocyclic groups such as, for example, pyrrolyl, pyrrolinyl,imidazoylyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl,triazolyl, tetrazolyl, pyrrolidinyl, imidazolidinyl, piperidyl,piperazinyl, homopiperazinyl, indolyl, isoindolyl, indolizinyl,benzimidazolyl, quinolyl, isoquinolyl, imidazopyridyl, indazolyl,benzotriazolyl, tetrazolo-pyridazinyl, pyranyl, furyl,1H-tetrahydropyranyl, tetrahydrofuranyl, thienyl, oxazolyl, isoxazolyl,oxadiazoyl, oxazolinyl, morpholinyl, benzofuranyl, benzoxazolyl,benzoxadiazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, benzothiazolyl,benzothiadiazolyl, benzofuranyl, or benzodioxyl and the like. Suchheterocyclyls are suitably substituted with lower alkyl or oxosubstituents.

As used herein unless otherwise specified, “acyl” includes for example,carboxy, esterified carboxy, carbamoyl, lower alkylcarbamoyl, loweralkanoyl, aroyl, heterocyclylcarbonyl, and the like. Esterified carboxyincludes substituted or unsubstituted lower alkoxycarbonyl such asmethoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,t-butoxycarbonyl, hexyloxycarbonyl, 2-iodoethoxycarbonyl,2,2,2-trichloroethoxycarbonyl, dimethylaminopropoxycarbonyl,dimethylaminoethoxycarbonyl; substituted or unsubstitutedaryloxycarbonyl such as phenoxycarbonyl, 4-nitrophenoxycarbonyl,2-naphthyloxycarbonyl; substituted or unsubstitutedar(lower)alkoxycarbonyl such as benzyloxycarbonyl, phenethyloxycarbonyl,benzhydryloxycarbonyl, 4-nitrobenzyloxycarbonyl,3-methoxy-4-nitrobenzyloxycarbonyl; and N-containingheterocyclyloxycarbonyl such as N-methylpiperidyloxycarbonyl and thelike.

As used herein unless otherwise specified, “halogen” is fluorine,chlorine, bromine or iodine.

As used herein unless otherwise specified, “C₁₋₆alkylhydrazino” may be2-mono or 2,2-di(C₁₋₆alkyl)hydrazino such as 2-methylhydrazino,2,2-dimethylhydrazino, 2-ethylhydrazino, 2,2-diethylhydrazino, or thelike.

As used herein unless otherwise specified, “C₁₋₆alkylaminoC₁₋₆alkyl”includes, for example, methylaminomethyl, dimethylaminomethyl,dimethylaminoethyl or the like.

“C₁₋₆alkanoyl” includes substituted or unsubstituted alkanoyls such asformyl, acetyl, propionylo, butyryl, isobutyryl, valeryl, isovaleryl,pivaloyl, hexanoyl, trifluoroacetyl or the like.

“aroyl” includes benzoyl, naphthoyl, toluoyl, di(t-butyl)benzoyl and thelike.

As used herein unless otherwise specified, “N-protective group” in“protected amino”, includes substituted or unsubstituted lower alkanyl(such as, for example, formyl, acetyl, propionyl, trifluoroacetyl),phthaloyl, lower alkoxycarbonyl (such as t-butoxycarbonyl,t-amyloxycarbonyl), substituted or unsubstituted aralkyloxycarbonyl(such as benzyloxycarbonyl, p-nitrobenzyloxycarbonyl),9-fluorenylmethoxycarbonyl, substituted or unsubstitutedarenesulfonyl(benzenesulfonyl, tosyl). Phthaloyl, t-butoxycarbonyl or9-fluorenylmethoxycarbonyl are preferred.

As used herein unless otherwise specified, “N-protective group” in“protected guanidino”, includes lower alkoxycarbonyl (such ast-butoxycarbonyl, t-amyloxycarbonyl).

As used herein unless otherwise specified, “hydroxy-protective group”includes substituted or unsubstituted arylmethyl (for example, benzyl,lower alkoxybenzyl), acyl, or substituted silyl (for example,t-butyldiphenylsilyl).

The above Formulas I, II, and III are shown without a definitivestereochemistry at certain positions. The present invention includes allstereoisomers of Formulas I, II, and III and pharmaceutically acceptablesalts thereof. Further, mixtures of stereoisomers as well as isolatedspecific stereoisomers are also included. During the course of thesynthetic procedures used to prepare such compounds, or in usingracemization or epimerization procedures known to those skilled in theart, the products of such procedures can be a mixture of stereoisomers.

The invention also encompasses a pharmaceutical composition that iscomprised of a compound of Formula I in combination with apharmaceutically acceptable carrier.

Preferably, the composition is comprised of a pharmaceuticallyacceptable carrier and a non-toxic therapeutically effective amount of acompound of Formula I as described above (or a pharmaceuticallyacceptable salt or N-oxide thereof).

Moreover, within this preferred embodiment, the invention encompasses apharmaceutical composition for the treatment of disease by theinhibition of the c-Kit kinase, which may be a wild-type or mutant formof the protein, comprising a pharmaceutically acceptable carrier and anon-toxic therapeutically effective amount of compound of Formula I asdescribed above (or a pharmaceutically acceptable salt or N-oxidethereof).

The compounds and compositions of the present invention are effectivefor treating mammals such as, for example, humans.

The term “pharmaceutically acceptable salts” refers to salts preparedfrom pharmaceutically acceptable non-toxic bases or acids. When thecompound of the present invention is acidic, its corresponding salt canbe conveniently prepared from pharmaceutically acceptable non-toxicbases, including inorganic bases and organic bases. Salts derived fromsuch inorganic bases include aluminum, ammonium, calcium, copper (ic andous), ferric, ferrous, lithium, magnesium, manganese (ic and ous),potassium, sodium, zinc and the like salts. Particularly preferred arethe ammonium, calcium, magnesium, potassium and sodium salts. Saltsderived from pharmaceutically acceptable organic non-toxic bases includesalts of primary, secondary, and tertiary amines, as well as cyclicamines and substituted amines such as naturally occurring andsynthesized substituted amines. Other pharmaceutically acceptableorganic non-toxic bases from which salts can be formed include ionexchange resins such as, for example, arginine, betaine, caffeine,choline, N′,N′-dibenzylethylenediamine, diethylamine,2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine,ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine,glucosamine, histidine, hydrabamine, isopropylamine, lysine,methylglucamine, morpholine, piperazine, piperidine, polyamine resins,procaine, purines, theobromine, triethylamine, trimethylamine,tripropylamine, tromethamine and the like.

When the compound of the present invention is basic, its correspondingsalt can be conveniently prepared from pharmaceutically acceptablenon-toxic acids, including inorganic and organic acids. Such acidsinclude, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic,citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic,hydrochloric, isethionic, lactic, maleic, malic, mandelic,methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric,succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.Particularly preferred are citric, hydrobromic, hydrochloric, maleic,phosphoric, sulfuric, methanesulfonic, and tartaric acids.

The pharmaceutical compositions of the present invention or used by themethods of the present invention comprise a compound represented byFormula I, II, or III (or a pharmaceutically acceptable salt or N-oxidethereof) as an active ingredient, a pharmaceutically acceptable carrierand optionally other therapeutic ingredients or adjuvants. Thecompositions include compositions suitable for oral, rectal, topical,and parenteral (including subcutaneous, intramuscular, and intravenous)administration, although the most suitable route in any given case willdepend on the particular host, and nature and severity of the conditionsfor which the active ingredient is being administered. Thepharmaceutical compositions may be conveniently presented in unit dosageform and prepared by any of the methods well known in the art ofpharmacy.

In practice, the compounds represented by Formula I, or pharmaceuticallyacceptable salts or N-oxides thereof, of this invention can be combinedas the active ingredient in intimate admixture with a pharmaceuticalcarrier according to conventional pharmaceutical compounding techniques.The carrier may take a wide variety of forms depending on the form ofpreparation desired for administration. E.g., oral or parenteral(including intravenous). Thus, the pharmaceutical compositions of thepresent invention can be presented as discrete units suitable for oraladministration such as capsules, cachets or tablets each containing apredetermined amount of the active ingredient. Further, the compositionscan be presented as a powder, as granules, as a solution, as asuspension in an aqueous liquid, as a non-aqueous liquid, as anoil-in-water emulsion, or as a water-in-oil liquid emulsion. In additionto the common dosage forms set out above, the compound represented byFormula I, or a pharmaceutically acceptable salt or N-oxide thereof, mayalso be administered by controlled release means and/or deliverydevices. The compositions may be prepared by any of the methods ofpharmacy. In general, such methods include a step of bringing intoassociation the active ingredient with the carrier that constitutes oneor more necessary ingredients. In general, the compositions are preparedby uniformly and intimately admixing the active ingredient with liquidcarriers or finely divided solid carriers or both. The product can thenbe conveniently shaped into the desired presentation.

Thus, the pharmaceutical compositions of this invention may include apharmaceutically acceptable carrier and a compound or a pharmaceuticallyacceptable salt or N-oxide of Formula I, II, or III. The compounds ofFormula I, II, or III, or pharmaceutically acceptable salts or N-oxidesthereof, can also be included in pharmaceutical compositions incombination with one or more other therapeutically active compounds.

The pharmaceutical compositions of this invention include apharmaceutically acceptable liposomal formulation containing a compoundof Formula I, II, or III or a pharmaceutically acceptable salt orN-oxide thereof.

The pharmaceutical carrier employed can be, for example, a solid,liquid, or gas. Examples of solid carriers include lactose, terra alba,sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, andstearic acid. Examples of liquid carriers are sugar syrup, peanut oil,olive oil, and water. Examples of gaseous carriers include carbondioxide and nitrogen.

In preparing the compositions for oral dosage form, any convenientpharmaceutical media may be employed. For example, water, glycols, oils,alcohols, flavoring agents, preservatives, coloring agents, and the likemay be used to form oral liquid preparations such as suspensions,elixirs and solutions; while carriers such as starches, sugars,microcrystalline cellulose, diluents, granulating agents, lubricants,binders, disintegrating agents, and the like may be used to form oralsolid preparations such as powders, capsules and tablets. Because oftheir ease of administration, tablets and capsules are the preferredoral dosage units whereby solid pharmaceutical carriers are employed.Optionally, tablets may be coated by standard aqueous or nonaqueoustechniques.

A tablet containing the composition of this invention may be prepared bycompression or molding, optionally with one or more accessoryingredients or adjuvants. Compressed tablets may be prepared bycompressing, in a suitable machine, the active ingredient in afree-flowing form such as powder or granules, optionally mixed with abinder, lubricant, inert diluent, surface active or dispersing agent orother such excipient. These excipients may be, for example, inertdiluents such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, or alginic acid; binding agents, for example,starch, gelatin or acacia; and lubricating agents, for example,magnesium stearate, stearic acid or talc. The tablets may be uncoated orthey may be coated by known techniques to delay disintegration andabsorption in the gastrointestinal tract and thereby provide a sustainedaction over a longer time. For example, a time delay material such asglyceryl monostearate or glyceryl distearate may be used.

In hard gelatin capsules, the active ingredient is mixed with an inertsolid diluent, for example, calcium carbonate, calcium phosphate orkaolin. In soft gelatin capsules, the active ingredient is mixed withwater or an oil medium, for example, peanut oil, liquid paraffin orolive oil. Molded tablets may be made by molding in a suitable machine,a mixture of the powdered compound moistened with an inert liquiddiluent. Each tablet preferably contains from about 0.05 mg to about 5 gof the active ingredient and each cachet or capsule preferablycontaining from about 0.05 mg to about 5 g of the active ingredient.

For example, a formulation intended for the oral administration tohumans may contain from about 0.5 mg to about 5 g of active agent,compounded with an appropriate and convenient amount of carriermaterial, which may vary from about 5 to about 95 percent of the totalcomposition. Unit dosage forms will generally contain between from about1 mg to about 2 g of the active ingredient, typically 25 mg, 50 mg, 100mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

Pharmaceutical compositions of the present invention suitable forparenteral administration may be prepared as solutions or suspensions ofthe active compounds in water. A suitable surfactant can be includedsuch as, for example, hydroxypropylcellulose. Dispersions can also beprepared in glycerol, liquid polyethylene glycols, and mixtures thereofin oils. Further, a preservative can be included to prevent thedetrimental growth of microorganisms.

Pharmaceutical compositions of the present invention suitable forinjectable use include sterile aqueous solutions or dispersions.Furthermore, the compositions can be in the form of sterile powders forthe extemporaneous preparation of such sterile injectable solutions ordispersions. In all cases, the final injectable form must be sterile andmust be effectively fluid for easy syringability. The pharmaceuticalcompositions must be stable under the conditions of manufacture andstorage; thus, preferably should be preserved against the contaminatingaction of microorganisms such as bacteria and fungi. The carrier can bea solvent or dispersion medium containing, for example, water, ethanol,polyol (e.g., glycerol, propylene glycol and liquid polyethyleneglycol), vegetable oils, and suitable mixtures thereof.

Pharmaceutical compositions of the present invention can be in a formsuitable for topical use such as, for example, an aerosol, cream,ointment, lotion, dusting powder, or the like. Further, the compositionscan be in a form suitable for use in transdermal devices. Theseformulations may be prepared, utilizing a compound represented byFormula I of this invention, or a pharmaceutically acceptable salt orN-oxide thereof, via conventional processing methods. As an example, acream or ointment is prepared by admixing hydrophilic material andwater, together with about 5 wt % to about 10 wt % of the compound, toproduce a cream or ointment having a desired consistency.

Pharmaceutical compositions of this invention can be in a form suitablefor rectal administration wherein the carrier is a solid. It ispreferable that the mixture forms unit dose suppositories. Suitablecarriers include cocoa butter and other materials commonly used in theart. The suppositories may be conveniently formed by first admixing thecomposition with the softened or melted carrier(s) followed by chillingand shaping in molds.

In addition to the aforementioned carrier ingredients, thepharmaceutical formulations described above may include, as appropriate,one or more additional carrier ingredients such as diluents, buffers,flavoring agents, binders, surface-active agents, thickeners,lubricants, preservatives (including anti-oxidants) and the like.Furthermore, other adjuvants can be included to render the formulationisotonic with the blood of the intended recipient. Compositionscontaining a compound described by Formula I, or pharmaceuticallyacceptable salts or N-oxides thereof, may also be prepared in powder orliquid concentrate form.

Generally, dosage levels on the order of from about 0.01 mg/kg to about150 mg/kg of body weight per day are useful in the treatment of theabove-indicated conditions, or alternatively about 0.5 mg to about 10 gper patient per day. For example, breast cancer, head and neck cancers,and gastrointestinal cancer such as colon, rectal or stomach cancer maybe effectively treated by the administration of from about 0.01 to 100mg of the compound per kilogram of body weight per day, or alternativelyabout 0.5 mg to about 7 g per patient per day.

Similarly, leukemia, ovarian, bronchial, lung, and pancreatic cancer maybe effectively treated by the administration of from about 0.01 to 100mg of the compound per kilogram of body weight per day, or alternativelyabout 0.5 mg to about 7 g per patient per day.

Mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST),small cell lung carcinoma (SCLC), sinonasal natural killer/T-celllymphoma, testicular cancer (seminoma), thyroid carcinoma, malignantmelanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenousleukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblasticleukemia, angiosarcoma, anaplastic large cell lymphoma, endometrialcarcinoma, and prostate carcinoma may be effectively treated by theadministration of from about 0.01 to 100 mg of the compound per kilogramof body weight per day, or alternatively about 0.5 mg to about 7 g perpatient per day.

It is understood, however, that the specific dose level for anyparticular patient will depend upon a variety of factors including theage, body weight, general health, sex, diet, time of administration,route of administration, rate of excretion, drug combination and theseverity of the particular disease undergoing therapy.

The compounds of the present invention, or pharmaceutically acceptablesalts or N-oxides thereof, can also be effectively administered inconjunction with other cancer therapeutic compounds. For example,cytotoxic agents and angiogenesis inhibiting agents can be advantageousco-agents with the compounds of the present invention. Accordingly, thepresent invention includes compositions comprising the compoundsrepresented by Formula I, or a pharmaceutically acceptable salt orN-oxide thereof, and a cytotoxic agent or an angiogenesis-inhibitingagent. The amounts of each can be therapeutically effective alone—inwhich case the additive effects can overcome cancers resistant totreatment by monotherapy. The amounts of any can also besubtherapeutic—to minimize adverse effects, particularly in sensitivepatients.

It is understood that the treatment of cancer depends on the type ofcancer. For example, lung cancer is treated differently as a first linetherapy than are colon cancer or breast cancer treated. Even within lungcancer, for example, first line therapy is different from second linetherapy, which in turn is different from third line therapy. Newlydiagnosed patients might be treated with cisplatinum containingregimens. Were that to fail, they move onto a second line therapy suchas a taxane. Finally, if that failed, they might get a tyrosine kinaseEGFR inhibitor as a third line therapy. Further, The regulatory approvalprocess differs from country to country. Accordingly, the acceptedtreatment regimens can differ from country to country. Nevertheless, thecompounds of the present invention, or pharmaceutically acceptable saltsor N-oxides thereof, can be beneficially co-administered in conjunctionor combination with other such cancer therapeutic compounds. Such othercompounds include, for example, a variety of cytotoxic agents(alkylators, DNA topoisomerase inhibitors, antimetabolites, tubulinbinders); inhibitors of angiogenesis; and different other forms oftherapies including kinase inhibitors such as Tarceva, monoclonalantibodies, and cancer vaccines. Other such compounds that can bebeneficially co-administered with the compounds of the present inventioninclude doxorubicin, vincristine, cisplatin, carboplatin, gemcitabine,and the taxanes. Thus, the compositions of the present invention includea compound according to Formula I, or a pharmaceutically acceptable saltor N-oxide thereof, and an anti-neoplastic, anti-tumor, anti-angiogenic,or chemotherapeutic agent.

The compounds of the present invention, or pharmaceutically acceptablesalts or N-oxides thereof, can also be effectively administered inconjunction with other therapeutic compounds, aside from cancer therapy.For example, therapeutic agents effective to ameliorate adverseside-effects can be advantageous co-agents with the compounds of thepresent invention.

Representative EXAMPLES of the present invention are summarized in Table1 below:

TABLE 1 R1

R2

Ex. 1 Ex. 2 Ex. 3 Ex. 4

Ex. 11 Ex. 5 Ex. 6 Ex. 7

Ex. 12 Ex. 9 Ex. 10 Ex. 8

I. Activated c-Kit Kinase Bench Assay

cDNA encoding the Kit tyrosine kinase domain was isolated from K562cells and cloned into a baculovirus expression vector for proteinexpression as a fusion protein with GST (Glutathione S-Transferase) ininsect cells. Following purification, the enzyme was incubated with ATPto generate a tyrosine phosphorylated, activated form of the enzyme,which was used in kinase assays to determine the ability of compounds toinhibit phosphorylation of an exogenous substrate by the Kit tyrosinekinase domain.

Phosphorylation of c-Kit Protein

The reagents used were as follows:

Column Buffer:

50 mM HEPES pH 7.4125 mM NaCl

10% Glycerol

1 mg/mL BSA

2 mM DTT

200 μM NaVO₃

Phosphorylation Buffer:

50 mM HEPES pH 7.4

125 mM NaCl

24 mM MgCl₂

1 mM MnCl₂

1% Glycerol

200 μM NaVO₃

2 mM DTT

2 mM ATP

75 μL purified GST-Kit tyrosine kinase protein (approximately 150 μg) isincubated with 225 μL phosphorylation buffer for 1 h at 30° C. In a coldroom, a desalting column (e.g. Pharmacia PD-10 column) is equilibratedusing 25 mL of column buffer. Phosphorylated protein is applied to thecolumn followed by sufficient column buffer to equal 2.5 mL total (inthis case 2.2 mL). The phosphorylated Kit protein is then eluted with3.5 mL column buffer, and collected into a tube containing 3.5 mLglycerol (final concentration of 50% glycerol). After mixing, aliquotsare stored at −20° C. or −70° C.

Assay of c-Kit Kinase Activity

Kinase activity is determined in an ELISA-based assay that measures theability of Kit to phosphorylate an exogenous substrate (poly Glu:Tyr) ontyrosine residues in the presence of ATP. Substrate phosphorylation ismonitored by quantitation of the degree of binding of an antibody thatrecognizes only the phosphorylated tyrosine residues within thesubstrate following incubation with Kit. The antibody used has areporter enzyme (e.g. horseradish peroxidase, HRP) covalently attached,such that binding of antibody to the phosphorylated substrate can bedetermined quantitatively by incubation with an appropriate HRPsubstrate (e.g. ABTS).

The stock reagents used are as follows:

13.3 μg/mL PGT stock solution: Add 66.7 μL 10 mg/mL PGT to 50 mL PBS.

1× wash buffer: Dilute 20× wash buffer (KPL #50-63-00) to 1× with H₂O.

Assay Buffer:

50 mM Hepes, pH 7.4

125 mM NaCl

24 mM MgCl₂

1 mM MnCl₂

1% Glycerol

200 μM Vanadate—add immediately prior to use

2 mM DTT—add immediately prior to use

Assay buffer+ATP: Add 5.8 μL of 75 mM ATP to 12 mL of assay buffer.

Activated GST-c-kit(TK): Dilute 1:500 in assay buffer.

Block Buffer:

PBS containing 0.5% Tween-20, 3% BSA

200 μM Vanadate—add immediately prior to use

pY20-HRP:

Add 6.2 μL of a 100 μg/mL stock of pY20-HRP to 10 mL of block buffer

ABTS substrate: KPL 3 50-66-06, use as provided

Assay Protocol

Each well of a 94-well immulon-4 microtitre plate is coated with 75 μLof 13.3 μg/mL PGT stock solution, incubated overnight at 37° C. andwashed once with 250 μL 1× wash buffer.

To the negative control wells, 50 μL of assay buffer (without ATP) areadded, all other wells contain 50 μL assay buffer+ATP. To positive andnegative control wells, 10 μL 5% DMSO is added, other wells contain 10μL of test compounds (at concentrations between 10 nM and 100 μM)dissolved in 5% DMSO.

30 μL of activated GST-c-kit are added to initiate the assay, which isincubated at RT for 30 min, and then stopped by the addition of 50μL/well of 0.5M EDTA. The plate is washed 3× with 1× wash buffer, andthen 75 μL of a phospho-tyrosine-specific antibody-HRP conjugate (e.g.pY20-HRP, Calbiochem) in block buffer are added. The plate is incubatedat RT for 2 h, and then washed 3× with 1× wash buffer. 100 μL of ABTSsubstrate are then added, the plate is incubated at RT for 30 min, andthe reaction stopped by the addition of 100 μL of 1% SDS. The reactionis quantitated by measuring the OD at 405/490 nM on a microtitre platereader.

Comparison of the assay signals obtained in the presence of compoundwith those of controls (in the presence and absence of ATP, with nocompound added), allows the degree of inhibition of kinase activity tobe determined over a range of compound concentrations. These inhibitionvalues are fitted to a sigmoidal dose-response inhibition curve todetermine the IC₅₀ values (i.e. the concentration of compound thatreduces the kinase activity to 50% of the control activity).

The compounds of this invention reduced the ability of Kit tophosphorylate poly(Glu:Tyr) in the above assay, thus demonstratingdirect inhibition of the c-Kit receptor tyrosine kinase activity. IC₅₀values in this assay were between 9 nM and 388 nM.

The compounds of the present invention surprisingly and unexpectedlydemonstrated better activity inhibiting c-Kit according to the aboveassay than the nearest similar thiophene compounds in the art (IC₅₀values in this assay of the compounds of this invention were less thanthe IC₅₀ values in this assay of the known nearest thiophene compounds).Further, the compounds of the present invention surprisingly andunexpectedly are more stable chemically than many of their respectiveregioisomers.

Experimental

The EXAMPLES of the present invention were prepared according to thefollowing procedures:

Referring to the scheme shown below for EXAMPLE 1, anilides of type 3may be prepared directly from esters such as compound 1 under Weinrebamidation conditions, whereby said esters are reacted with anilines asexemplified by compound 2 in the presence of alkyl aluminum reagentssuch as (but not limited to) trimethylaluminum or chlorodimethylaluminumin a neutral solvent such as toluene or dichloromethane (SyntheticCommunications, (1982), 12, 989).

Compounds such as 3 bearing a primary amino functionality may then bereacted with aldehydes under reducing conditions to give secondaryamines such as EXAMPLE 1—for example in the presence of a mixture oftriethylsilane and trifluoroacetic acid, or other reagents such as (butnot limited to) sodium cyanoborohydride, sodium triacetoxyborohydride,sodium borohydride and hydrogen.

EXAMPLE 1 N-(4-trifluoromethoxyphenyl)3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide

EXAMPLE 1 was prepared by the following procedure:

Part 1:

N-(4-trifluoromethoxyphenyl) 3-Aminothiophene-2-carboxamide: To astirred solution of 4-trifluoromethoxyaniline (7.8 g, 44.5 mmol) intoluene (50 mL) under nitrogen was added trimethylaluminum (2M intoluene, 26.7 mL, 53.4 mmol). The mixture was stirred at RT for 16 h.Methyl 3-amino-2-thiophenecarboxylate (7 g, 44.5 mmol) was added and theresulting solution was stirred at reflux (oil bath temperature: 130° C.)under nitrogen for 24 h. After cooling to RT, saturated sodiumbicarbonate solution (100 mL) was added dropwise with caution and themixture was stirred at RT for 30 min. The product was extracted intodichloromethane (3×100 mL), and the organic layer was dried over Na₂SO₄,and concentrated to yield a thick oil, which was then triturated with amixture of hexane/ethyl acetate to afford N-(4-trifluoromethoxyphenyl)3-Aminothiophene-2-carboxamide as a brown solid. ¹H-NMR (400 MHz/CD₃OD):δ=6.65 (d, J=5.6 Hz, 1H), 7.23 (d, J=8.4 Hz, 2H), 7.39 (d, J=5.2 Hz,1H), 7.67 (d, J=9.2 Hz, 2H). MS (ES⁺): 303 [MH⁺].

Part 2:

N-(4-trifluoromethoxyphenyl)3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide: A solution ofN-(4-trifluoromethoxyphenyl) 3-aminothiophene-2-carboxamide (1 g, 3.31mmol) and quinoline-4-carboxaldehyde (347 mg, 2.21 mmol) intrifluoroacetic acid:dichloromethane (1:1, 30 mL) was heated at refluxfor 2 h under nitrogen. The reaction was cooled to RT and triethylsilane(0.71 mL, 4.42 mmol) was added. The resulting solution was then stirredat reflux for 16 h under nitrogen. After cooling to RT, the reactionmixture was evaporated under reduced pressure and the residue waspartitioned between ethyl acetate (3×100 mL) and saturated sodiumbicarbonate solution (50 mL). The organic layers were dried over Na₂SO₄,filtered, and concentrated. The residue was purified by silica gelchromatography (20-30% ethyl acetate in hexane) to give EXAMPLE 1 as alight yellow solid, mp: 168-170° C. ¹H-NMR (400 MHz/CDCl₃):δ=5.01 (d,J=6.2 Hz, 2H), 6.56 (d, J=5.4 Hz, 1H), 7.12 (s, 1H), 7.22 (d, J=8.7 Hz,2H), 7.25 (s, 1H), 7.44 (d, J=4.3 Hz, 1H), 7.58 (d, J=9.0 Hz, 2H), 7.62(t, J=8.2 Hz, 1H), 7.76 (t, J=8.3 Hz, 1H), 8.02 (d, J=7.5 Hz, 2H), 8.17(d, J=8.3 Hz, 1H), 8.86 (d, J=4.5 Hz, 1H). MS (ES⁺): 444 [MH⁺]. ¹³C-NMR(400 MHz/CDCl₃): δ=45.9, 101.4, 117.9, 118.9, 119.5, 121.9, 122.0,122.6, 126.5, 127.2, 129.1, 129.7, 130.6, 136.8, 144.5, 145.4, 148.3,150.7, 155.9, 163.8. Anal. Calcd for C₂₂H₁₆F₃N₃O₂S: C, 59.59; H, 3.64;N, 9.48; F, 12.85; S, 7.23. Found: C, 59.59; H, 3.67; N, 9.46; F, 13.01;S, 7.23.

EXAMPLE 2 N-(4-bromo-3-methylphenyl)3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxamide

EXAMPLE 2 was prepared according to the procedure described above forEXAMPLE 1, using 4-bromo-3-methylaniline instead of4-trifluoromethoxyaniline. MS (ES⁺): 452, 454 [MH⁺]

EXAMPLE 3 N-(2,2,3,3-tetrafluorobenzodioxan-6-yl)3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxamide

EXAMPLE 3 was prepared according to the procedure described above forEXAMPLE 1, using 6-amino-2,2,3,3-tetrafluorobenzodioxan instead of4-trifluoromethoxyaniline. MS (ES⁺): 490 [MH⁺]

EXAMPLE 4 N-(4-chlorophenyl)3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxamide

EXAMPLE 4 was prepared according to the procedure described above forEXAMPLE 1, using 4-chloroaniline instead of 4-trifluoromethoxyaniline.MS (ES⁺): 394, 396 [MH⁺]

EXAMPLE 54-{[2-(4-Bromo-3-methylphenylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylicacid methylamide

To a stirred solution of N-(4-bromo-3-methylphenyl)3-aminothiophene-2-carboxamide (1equiv, prepared as described above forEXAMPLE 1, part 1, using 4-bromo-3-methylaniline instead of4-trifluoromethoxyaniline) in THF at 0° C. in an open flask, was added2-(N-methylcarbamoyl)pyridine-4-carboxaldehyde (prepared as described inInternational Patent Publication No. WO 01/23375) (1.1equiv) in THF and4M H₂SO₄ (0.1equiv) and the mixture was stirred for 30 min at 0° C.Sodium borohydride (1equiv) was added portionwise and the mixture wasallowed to warm to RT and stirred for 2 h. Water was then added, themixture was basified to pH 12 with 2M sodium hydroxide solution, and theresulting product was extracted into ethyl acetate. The combinedextracts were washed with water followed by brine, dried (MgSO₄),filtered and concentrated in vacuo to afford a yellow semisolid, whichwas purified by column chromatography eluting with a 95:5 mixture ofhexane:ethyl acetate increasing gradually to a 50:50 mixture. MS (ES⁺):459, 461 [MH⁺]

EXAMPLE 64-{[2-(2,2,3,3-Tetrafluorobenzodioxan-6-ylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylicacid methylamide

EXAMPLE 6 was prepared according to the procedure described above forEXAMPLE 5, using N-(2,2,3,3-tetrafluorobenzodioxan-6-yl)3-aminothiophene-2-carboxamide (prepared as described above for EXAMPLE1, part 1, using 6-amino-2,2,3,3-tetrafluorobenzodioxan instead of4-trifluoromethoxyaniline). MS (ES⁺): 497 [MH⁺]

EXAMPLE 74-{[2-(4-Chlorophenylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylicacid methylamide

EXAMPLE 7 was prepared according to the procedure described above forEXAMPLE 5, using N-(4-chlorophenyl) 3-aminothiophene-2-carboxamide(prepared as described above for EXAMPLE 1, part 1, using4-chloroaniline instead of 4-trifluoromethoxyaniline). MS (ES⁺): 401,403 [MH⁺]

EXAMPLE 8 N-(4-chlorophenyl)3-[(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide

Part 1:

7-Azaindole-3-carboxaldehyde: Phosphorus oxychloride (36.5 mL) was addeddropwise to cooled solution of DMF (40 mL) while maintaining thetemperature below 10° C. The resulting solution was further cooled to 5°C. and a solution of 7-azaindole in DMF (40 mL) was added slowly over30-40 min, maintaining the temperature below 25° C. The mixture washeated at 95° C. for 48 h then cooled to 35° C. and added cautiouslywith stirring over an hour to a cooled solution of saturated aqueoussodium bicarbonate solution (800 mL). The mixture was extracted withethyl acetate (4×500 mL) and the combined extracts washed with water(500 mL) and brine (500 mL), then dried (MgSO₄), filtered andconcentrated in vacuo to afford a dark brown semi-solid. This crudeproduct was purified using column chromatography eluting with a 50:50mixture of ethyl acetate:hexane, gradually increasing to 90:10 mixture.1H-NMR (400 MHz/D₆-DMSO): δ=7.25 (m, 1H), 8.38 (m, 2H), 8.42 (s, 1H),9.92 (s, 1H), 12.62 (br.s, 1H). MS (ES⁺): 147 [MH⁺].

Part 2:

N-(4-chlorophenyl)3-[(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide:Prepared according to the procedure described in EXAMPLE 5 usingN-(4-chlorophenyl) 3-aminothiophene-2-carboxamide (prepared as describedin EXAMPLE 1, part 1, using 4-chloroaniline instead of4-trifluoromethoxyaniline) and 7-azaindole-3-carboxaldehyde (EXAMPLE 8,part 1) instead of 2-(N-methylcarbamoyl)pyridine-4-carboxaldehyde. MS(ES⁺): 383, 385 [MH⁺]

EXAMPLE 9 N-(4-bromo-3-methylphenyl)3-[(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide

EXAMPLE 9 was prepared according to the procedure described in EXAMPLE 5using N-(4-bromo-3-methylphenyl) 3-aminothiophene-2-carboxamide(prepared as described in EXAMPLE 1, part 1, using4-bromo-3-methylaniline instead of 4-trifluoromethoxyaniline) and7-azaindole-3-carboxaldehyde (EXAMPLE 8, part 1) instead of2-(N-methylcarbamoyl)pyridine-4-carboxaldehyde. MS (ES⁺): 441, 443 [MH⁺]

EXAMPLE 10 N-(2,2,3,3-tetrafluorobenzodioxan-6-yl)3-[(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide

EXAMPLE 10 was prepared according to the procedure described in EXAMPLE5 using N-(2,2,3,3-tetrafluorobenzodioxan-6-yl)3-aminothiophene-2-carboxamide (prepared as described in example 1 part1, using 6-amino-2,2,3,3-tetrafluorobenzodioxan instead of4-trifluoromethoxyaniline) and 7-azaindole-3-carboxaldehyde (EXAMPLE 8,part 1) instead of 2-(N-methylcarbamoyl)pyridine-4-carboxaldehyde. MS(ES⁺): 479 [MH⁺]

EXAMPLE 11N-{[2-(4-Trifluoromethoxyphenylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylicacid methylamide

EXAMPLE 11 was prepared according to the procedure described above forEXAMPLE 5 using N-(4-trifluoromethoxyphenyl)3-aminothiophene-2-carboxamide (prepared as described above for EXAMPLE1). MS (ES⁺): 451 [MH⁺]

EXAMPLE 13N-(4-Trifluoromethoxy)phenyl-3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxamide

Part 1:

4-Chloro-1H-pyrrolo[2,3-b]pyridine: 1H-Pyrrolo[2,3-b]pyridine 7-oxidewas added slowly to 200 mL POCl₃ and the resulting mixture stirred at80° C. overnight. The excess POCl₃ was then removed in vacuo and theresidue treated with 500 mL H₂O and basified with saturated K₂CO₃ (aq),prior to extraction with EtOAc (2×300 mL). The combined extracts werewashed with water and brine, dried over anhydrous sodium sulfate andconcentrated in vacuo to give 4-Chloro-1H-pyrrolo[2,3-b]pyridine (12.9g, 76%). MS (ES+): 153 [MH⁺].

Part 2:

4-Iodo-1H-pyrrolo[2,3-b]pyridine: To a solution of4-Chloro-1H-pyrrolo[2,3-b]pyridine (12.9 g, 84.3 mmol) and NaI (40 g,168 mmol) in acetonitrile (150 mL) was slowly added acetyl chloride(12.6 mL, 176 mmol). The mixture was allowed to stir at 80° C. for 4days, and then the excess acetonitrile was removed in vacuo. 300 mL of10% K₂CO₃ (aq) was added to the residue and the mixture extracted withCH₂Cl₂ (3×100 mL). The combined organic extracts were washed with 10%sodium bisulfite (aq) and brine, dried over anhydrous sodium sulfate andconcentrated in vacuo to give crude product (22.2 g). To a solution ofthis crude product in THF (150 mL) was added 1M NaOH (100 mL). Themixture was stirred at room temperature for 2 hr prior to evaporation ofthe solvent in vacuo, dilution with water and extraction with CH₂Cl₂.The extracts were washed with brine, dried over anhydrous sodium sulfateand concentrated in vacuo. The resulting brown solid was purified bychromatography over silica gel and recrystallized from acetonitrile togive pure 4-Iodo-1H-pyrrolo[2,3-b]pyridine (9.75 g, 48%). MS (ES+): 245[MH⁺].

Part 3:

1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile: To a solution of (4.7 g, 19.3mmol) of 4-Iodo-1H-pyrrolo[2,3-b]pyridine in degassed DMF (25 mL) wasadded Pd₂(dba)₃ (10 mg), dppf (15 mg), degassed H₂O (2 mL) and Zn(CN)₂(1.4 g, 11.6 mmol). The mixture was stirred at 90° C. under nitrogen for20 hr, then cooled to 70° C. and 75 mL of a 4:1:4 mixture of saturatedNH₄Cl:NH₄OH:H₂O was added. The mixture was stirred at 5° C. for 20 min.and the resulting precipitate filtered off, washed with 75 mL 4:1:5mixture of saturated NH₄Cl:NH₄OH:H₂O, 500 mL H₂O and 100 mL toluene,then dried in vacuo to give 2.06 g (74%)1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile. MS (ES+): 143 [MH⁺]. ¹H NMR(DMSO-d₆, 400 MHz): δ 6.65 (d, 1H, J=3.2), 7.56 (d, 1H, J=4.8 Hz), 7.84(d, 1H, J=4.0 Hz), 8.40 (d, 1H, J=4.8 Hz).

Part 4:

1H-Pyrrolo[2,3-b]pyridine-4-carboxaldehyde: To a solution of (200 mg,1.4 mmol) of 1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile in THF (7 mL) at−78° C. under nitrogen was added Dibal-H (1.0 M in toluene, 3.07 mL,3.07 mmol). The reaction mixture was stirred at −78° C. for 1 hr, warmedto 55° C. and stirred for additional 2 hr. One additional equivalent ofDIBAL-H (1.4 mL, 1.4 mmol) was added and the mixture stirred at 55° C.for 2 hr. The mixture was cooled to 5° C., acidified with 2 M HCl andstirred for 15 min. The mixture was then neutralized with saturatedNaHCO₃ (aq), extracted with CH₂Cl₂ (5×25 mL), washed with brine, driedover anhydrous sodium sulfate and concentrated in vacuo to give1H-Pyrrolo[2,3-b]pyridine-4-carboxaldehyde (107 mg, 52%). MS (ES+): 146[MH⁺]. ¹H NMR (DMSO-d₆, 400 MHz): δ 7.22 (d, 1H, J=3.6 Hz), 7.57 (d, 1H,J=4.8 Hz), 7.67 (d, 1H, J=2.4 Hz), 8.61 (d, 1H, J=5.2 Hz), 10.42 (s,1H).

Part 5:

Methyl3-[(1H-Pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxylate: Asolution of 3-aminothiophene-2-carboxylic acid methyl ester (110 mg,0.701 mmol), and 1H-Pyrrolo[2,3-b]pyridine-4-carboxaldehyde (107 mg,0.736 mmol) in TFA/CH₂Cl₂ (2 mL/2 mL) was stirred at 50° C. for 3 hr.The solution was cooled to 0° C. and triethylsilane (0.224 mL, 1.40mmol) was added dropwise. The mixture was then stirred at 50° C. for 4hr and treated with 2 N NaOH (aq)(to pH 6) and then saturated NaHCO₃(aq)(to pH 8). The organic layer was separated and the aqueous layer wasextracted with CH₂Cl₂ (3×10 mL). The organic extracts were combined,washed with brine, dried over anhydrous sodium sulfate and concentratedin vacuo. The residue was purified by chromatography over silica gel(gradient of 20% EtOAc/Hexanes to 70% EtOAc/Hexanes) to yield methyl3-[(1H-Pyrrolo[2,3-b]pyridin-4-ylmethyl) amino]thiophene-2-carboxylate(98 mg, 49%). MS (ES+): 287 [MH⁺]. ¹H NMR (DMSO-d₆, 400 MHz): δ 3.75 (s,3H), 4.84 (d, 2H, J=4.4 Hz), 6.74 (dd, 1H, J=2.8 Hz & 2.0 Hz), 6.70 (d,1H, J=5.6 Hz), 7.01 (d, 1H, J=4.8 Hz), 7.51 (t, 1H, J=2.4 Hz), 7.61 (d,1H, J=5.2 Hz), 8.18 (d, 1H, J=4.8 Hz).

Part 6:

N-(4-Trifluoromethoxy)phenyl-3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxamide:To a solution of 4-trifluoromethoxyaniline (0.381 mL, 1.74 mmol) inanhydrous toluene (5 mL) was added AlMe₃ (2.0 M in toluene, 0.520 mL,1.4 mmol) and the solution was stirred at RT overnight. Methyl3-[(1H-Pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxylate(100 mg, 0.348 mmol) was added and the mixture was stirred at 130° C.overnight prior to cooling to room temperature and treatment with 15 mLof saturated NaHCO₃ (aq). After stirring for 1 hr the mixture wasfiltered, the filtrate layers separated, and the aqueous layer wasextracted with CH₂Cl₂ (3×10 mL). The isolated solid was dissolved in 15mL CH₂Cl₂ and all of the organic solutions (toluene and CH₂Cl₂) werecombined, washed with brine, dried over anhydrous sodium sulfate andconcentrated in vacuo. The residue was purified by chromatography oversilica gel (gradient of 20% EtOAc/Hexanes to 50% EtOAc/Hexanes) to yieldN-(4-Trifluoromethoxy)phenyl-3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxamide(93 mg, 62%). MS (ES+): 432 [MH⁺]. ¹H NMR (DMSO-d₆, 400 MHz): δ 4.81 (d,2H, J=6.4 Hz), 6.62 (dd, 1H, J=3.6 & 1.6 Hz), 6.78 (d, 1H, J=5.6 Hz),6.99 (d, 1H, J=4.8 Hz), 7.31 (d, 2H, J=8.8 Hz), 7.45 (dd, 1H, J=2.8 &3.2 Hz), 7.59 (d, 1H, J=5.6 Hz, 1H), 7.79 (ddd, 2H, J=8.8, 3.2 & 2.0Hz), 8.08 (t, 1H, J=6.4 Hz), 8.15 (d, 1H, J=4.8 Hz), 9.54 (s, 1H).

The following analogues were prepared using methyl3-[(1H-Pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxylate(EXAMPLE 13, part 5) and the appropriate aniline, according to theprocedure described above for EXAMPLE 13, part 6.

EXAMPLE 14N-(4-chlorophenyl)-3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxamide:

(5.1 mg, 4%). MS (ES+): 383 [MH⁺].

EXAMPLE 153-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)thiophene-2-carboxamide:

(19.4 mg, 16%). MS (ES+): 479 [MH⁺].

EXAMPLE 164-Methyl-N-(4-trifluoromethoxyphenyl)phenyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide:

Prepared according to the procedure described for EXAMPLE 13, parts 5and 6, utilizing methyl 3-amino-4-methylthiophene-2-carboxylate,quinoline-4-carboxaldehyde and 4-(trifluoromethoxy)aniline as startingmaterials. MS (ES+): 458 [MH⁺], 459 [MH²⁺]. ¹H NMR (CDCl₃, 400 MHz): δ2.15 (d, 3H, J=1.2 Hz), 5.01 (d, 2H, J=7.2 Hz), 6.98 (d, 1H, J=1.2 Hz),7.17-7.24 (m, 3H), 7.51-7.54 (m, 3H), 7.58 (ddd, 1H, J=8.0, 6.4, 1.2Hz), 7.74 (ddd, 1H, J=8.0, 6.8, 1.2 Hz), 7.86 (bs, 1H), 7.97 (dd, 1H,J=8.8, 0.8 Hz), 8.16 (d, 1H, J=8.0 Hz), 8.89 (d, 1H, J=4.8 Hz).

The following examples were prepared similarly, utilising theappropriate aniline in each case.

EXAMPLE 17N-(4-chlorophenyl)-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide:

MS (ES+): 408, 410 [MH⁺]

EXAMPLE 18N-(4-bromo-3-methylphenyl)-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide:

MS (ES+): 467, 469 [MH⁺]

EXAMPLE 194-Methyl-3-[(quinolin-4-ylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)thiophene-2-carboxamide:

MS (ES+): 503 [MH⁺]

EXAMPLE 203-{[(1-oxidoquinolin-4-yl)methyl]amino}-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

Part 1:

Quinolin-4-ylmethanol

A solution of quinoline-4-carbaldehyde (0.50 g, 3.24 mmol) dissolved inmethanol (5 mL) was cooled to 0° C. Sodium borohydride (0.11 g, 2.91mmol) was then added portion-wise. After 1 h of stirring at 0° C., 2MHCl (aq) was added drop-wise until pH˜5. The methanol was thenevaporated in vacuo and the aqueous phase was neutralized by addition ofsaturated aqueous NaHCO₃. The aqueous solution was extracted with CH₂Cl₂(3×) and the combined organic extracts were washed with saturated NaHCO₃(aq) and brine. The organic solution was dried over Na₂SO₄, filtered,and concentrated in vacuo to yield quinolin-4-ylmethanol as a yellowsolid. MS (ES+): 160 [MH⁺]. ¹H NMR (CDCl₃, 400 MHz): δ 2.41 (bs, 1H),5.25 (bs, 2H), 7.55 (ddd, J=4.4, 1.2, 1.2 Hz, 1H), 7.58 (ddd, J=8.4,7.2, 1.2 Hz, 1H), 7.73 (ddd, J=8.4, 6.8, 1.6 Hz, 1H), 7.97 (ddd, J=8.4,1.2, 0.4 Hz, 1H), 8.14 (ddd, J=8.0, 1.2, 0.4 Hz, 1H), 8.90 (d, J=4.4 Hz,1H).

Part 2:

(1-Oxidoquinolin-4-yl)methanol

To a solution of quinolin-4-ylmethanol (0.20 g, 1.26 mmol) dissolved inCH₂Cl₂ (10 mL), which was cooled to 0° C., was added m-chloroperbenzoicacid (57-86% w/w in H₂O, 0.50 mg) in one portion. The reaction wasallowed to slowly warm to room temperature while stirring. After 17.5 h,the resulting solid was filtered and washed with CH₂Cl₂ to yield(1-oxidoquinolin-4-yl)methanol as a white solid. MS (ES+): 176 [MH⁺].

Part 3:

Quinoline-4-carbaldehyde 1-oxide

To a vigorously stirring suspension of (1-oxidoquinolin-4-yl)methanol(0.10 g, 0.57 mmol) in acetonitrile (10 mL) was added Dess-Martinperiodinane (0.47 g, 0.63 mmol). After 1 h, 2M NaOH (aq, 2 mL) and ethylacetate (105 mL) were added and the reaction was stirred for 5 min. Thelayers were then separated and the organic phase was washed withsaturated NaHCO₃ (aq), brine, and dried over MgSO₄, filtered, andconcentrated in vacuo to a light yellow solid. MS (ES+): 174 [MH⁺].

(This intermediate may also be prepared as described in Heterocycles(2003), 60(4), 953).

Part 4:

3-{[(1-Oxidoquinolin-4-yl)methyl]amino}-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

A solution of quinoline-4-carboxaldehyde 1-oxide (0.12 g, 0.69 mmol),3-amino-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (0.21 g,0.69 mmol), dichloromethane (2 ml) and trifluoroacetic acid (2 ml) washeated at 50° C. for 2 hr, then cooled to room temperature, treated withtriethylsilane (0.22 ml, 1.38 mmol) and stirred at 50° C. for another 2h. After this time the mixture was diluted with water (40 ml), basified(pH 9) with 2M NaOH (aq) and extracted with ethyl acetate (3×20 ml). Theextracts were washed with water (30 ml) and brine (30 ml), then dried(MgSO₄) and concentrated in vacuo to give crude product. This materialwas chromatographed over silica gel eluting with 15%acetonitrile/CH₂Cl₂, and the isolated product further purified bycrystallization from acetonitrile to give3-{[(1-oxidoquinolin-4-yl)methyl]amino}-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide.MS (ES+): 460 [MH⁺]. ¹H NMR (DMSO-d₆, 400 MHz): δ 5.00 (s, 2H), 6.87 (d,J=5.6 Hz, 1H), 7.25-7.40 (m, 3H), 7.65 (d, J=5.3 Hz, 1H), 7.73-7.91 (m,4H), 8.0 (t, J=6.4 Hz, 1H), 8.30 (d, J=7.1 Hz, 1H), 8.56 (d, J=6.3 Hz,1H), 8.61 (d, J=8.3 Hz, 1H), 9.60 (s, 1H).

1. A compound represented by Formula (I):

or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1 is

R2 is

 and R3 is C₀₋₄alkyl.
 2. The compound according to claim 1, or apharmaceutically acceptable salt or N-oxide thereof, wherein R2 is


3. The compound according to claim 1, or a pharmaceutically acceptablesalt or N-oxide thereof, wherein R2 is

and R3 is hydrogen.
 4. The compound according to claim 1, or apharmaceutically acceptable salt or N-oxide thereof, wherein R2 is


5. The compound according to claim 1, or a pharmaceutically acceptablesalt or N-oxide thereof, wherein R2 is

and R3 is hydrogen.
 6. The compound according to claim 1, or apharmaceutically acceptable salt or N-oxide thereof, wherein R2 is


7. The compound according to claim 1, or a pharmaceutically acceptablesalt or N-oxide thereof, wherein R2 is

and R3 is C₀₋₄alkyl.
 8. The compound according to claim 1, or apharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

and R3 is hydrogen.
 9. The compound according to claim 1, or apharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

and R3 is C₀₋₄alkyl.
 10. A composition comprising a compound accordingto claim 1, or a pharmaceutically acceptable salt or N-oxide thereof,and a pharmaceutically acceptable carrier.
 11. A composition comprisinga compound according to claim 1, or a pharmaceutically acceptable saltor N-oxide thereof; and an anti-neoplastic, anti-tumor, anti-angiogenic,or chemotherapeutic agent.
 12. A composition comprising a compoundaccording to claim 1, or a pharmaceutically acceptable salt or N-oxidethereof, and a cytotoxic cancer therapeutic agent.
 13. A compositioncomprising a compound according to claim 1, or a pharmaceuticallyacceptable salt or N-oxide thereof, and an angiogenesis inhibitingcancer therapeutic agent.
 14. A compound consisting ofN-(4-trifluoromethoxyphenyl)3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;N-(4-bromo-3-methylphenyl)3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;N-(2,2,3,3-tetrafluorobenzodioxan-6-yl)3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;N-(4-chlorophenyl)3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;4-{[2-(4-bromo-3-methylphenylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylicacid methylamide;4-{[2-(2,2,3,3-tetrafluorobenzodioxan-6-ylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylicacid methylamide;4-{[2-(4-chlorophenylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylicacid methylamide; N-(4-chlorophenyl)3-[(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide;N-(4-bromo-3-methylphenyl)3-[(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide;N-(2,2,3,3-tetrafluorobenzodioxan-6-yl)3-[(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide;N-{[2-(4-trifluoromethoxyphenylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylicacid methylamide; andN-(4-Trifluoromethoxy)phenyl-3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxamide;N-(4-chlorophenyl)-3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxamide;3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)thiophene-2-carboxamide;4-Methyl-N-(4-trifluoromethoxyphenyl)phenyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;N-(4-chlorophenyl)-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;N-(4-bromo-3-methylphenyl)-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;4-Methyl-3-[(quinolin-4-ylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)thiophene-2-carboxamide;3-{[(1-oxidoquinolin-4-yl)methyl]amino}-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamideor a pharmaceutically acceptable salt, or N-oxide, thereof.
 15. A methodof treatment of hyperproliferative disorder comprising a step ofadministering an effective amount of the compound according to claim 1wherein the hyperproliferative disorder is selected from the groupconsisting of breast cancer, head cancer, neck cancer, gastrointestinalcancer, leukemia, ovarian, bronchial, lunch or pancreatic cancer. 16.The method of claim 15 wherein the hyperproliferative disorder issinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma),thyroid carcinoma, malignant melanoma, adenoid cystic carcinoma,angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, orprostate carcinoma.